https://www.live-feeds.com/feed/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductionsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductionshttps://www.live-feeds.com/feed/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductions#u57729Sat, 05 Sep 2026 03:56:46 +0000Ultragenyx Pharmaceutical shares dropped between 40.3% and 44% in early September 2026 after its Phase 3 Aspire trial for apazunersen (GTX-102) failed. The drug, an antisense oligonucleotide designed to treat the rare Angelman syndrome, did not meet its primary or key secondary cognitive and functional endpoints. In response to the failure, the company is planning "significant expense reductions" and a review of the program. Despite the setback, the FDA confirmed that Ultragenyx's recently approved GENGLYCOS gene therapy for glycogen storage disease type Ia qualifies for a rare